Close

Opexa Therapeutics' (OPXA) Phase 2b Abili-T Trial of Tcelnaa in Secondary Progressive MS Misses Primary Endpoint

October 28, 2016 8:34 AM EDT Send to a Friend
Opexa Therapeutics (Nasdaq: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, today announced that the Phase 2b Abili-T ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login